Logo

A

Agilent Technologies, Inc.

A

Agilent Technologies, Inc. • NYSE
$153.50 ▼ -0.56% (-0.87)
Market Cap $43.52 B
52w High $160.27
52w Low $96.43
Dividend Yield 0.99%
P/E 33.59
Volume 1.53M
Outstanding Shares 283.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $1.861B ▲ $521M ▼ $434M ▲ 23.321% ▲ $-1.52 ▼ $540M ▲
Q3-2025 $1.738B ▲ $554M ▼ $336M ▲ 19.333% ▲ $1.18 ▲ $466M ▲
Q2-2025 $1.668B ▼ $566M ▲ $215M ▼ 12.89% ▼ $0.75 ▼ $362M ▼
Q1-2025 $1.681B ▼ $523M ▲ $318M ▼ 18.917% ▼ $1.12 ▼ $467M ▼
Q4-2024 $1.701B $508M $351M 20.635% $1.23 $502M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $1.789B ▲ $12.727B ▲ $5.986B ▲ $6.741B ▲
Q3-2025 $1.535B ▲ $12.226B ▲ $5.856B ▼ $6.37B ▲
Q2-2025 $1.486B ▲ $12.158B ▲ $6.022B ▲ $6.136B ▲
Q1-2025 $1.467B ▲ $11.914B ▲ $5.887B ▼ $6.027B ▲
Q4-2024 $1.329B $11.846B $5.948B $5.898B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $434M ▲ $545M ▲ $-90M ▲ $-200M ▲ $254M ▲ $452M ▼
Q3-2025 $336M ▲ $362M ▲ $-96M ▲ $-219M ▼ $49M ▲ $573M ▲
Q2-2025 $215M ▼ $221M ▼ $-114M ▼ $-116M ▲ $19M ▼ $107M ▼
Q1-2025 $318M ▼ $431M ▼ $-94M ▲ $-180M ▼ $138M ▲ $334M ▼
Q4-2024 $351M $481M $-954M $25M $-450M $388M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Agilent CrossLab
Agilent CrossLab
 $430.00M ▲$700.00M ▲$710.00M ▲$740.00M ▲
Applied Markets
Applied Markets
 $0 ▲$340.00M ▲$300.00M ▼$320.00M ▲
Life Sciences and Applied Markets
Life Sciences and Applied Markets
 $830.00M ▲$650.00M ▼$650.00M ▲$670.00M ▲
Diagnostics and Genomics
Diagnostics and Genomics
 $440.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Agilent shows a picture of solid profitability with some top-line softness. Revenue has flattened and even dipped recently, which suggests a more challenging demand environment, especially after a strong run-up earlier in the decade. Despite that, gross margins remain healthy, and operating profit and net income have held up well, indicating good cost control and pricing power. Earnings per share have continued to grow, helped by efficiency and likely some share count management, even without strong revenue growth. Overall, this is a business that is earning well on each dollar of sales, but needs to re-ignite growth rather than just rely on margins and efficiencies.

Balance Sheet

Balance Sheet The balance sheet looks generally sound but a bit more leveraged than a few years ago. Total assets have grown, and shareholder equity has edged up, which is a positive sign of value being built over time. However, debt has increased meaningfully, which raises financial leverage and adds some risk if conditions worsen. Cash on hand moves around but appears adequate relative to operations. In summary, Agilent has a solid capital base and good asset quality, but investors should note the gradual shift toward more debt funding.

Cash Flow

Cash Flow Cash generation is a key strength. Operating cash flow is robust and has improved compared with earlier years, even as revenue has softened. Free cash flow remains solidly positive, showing that after funding its capital investments, the company still generates a meaningful surplus. Capital spending has been rising, but not aggressively, suggesting a balanced approach: investing in the business without stretching the cash profile. Overall, the company appears self-funding, with enough cash flow to support operations, investments, and capital return policies if desired.

Competitive Edge

Competitive Edge Agilent holds a strong position in analytical instruments, diagnostics, and lab services, built over decades and reinforced by its Hewlett-Packard heritage. Its equipment is deeply embedded in customer workflows, which makes switching to competitors costly and disruptive for labs. The CrossLab services business further strengthens this “stickiness” by servicing both Agilent and non-Agilent instruments, embedding the company into customers’ day-to-day operations. Brand strength, a large installed base, and integrated hardware–software–services offerings create a meaningful moat, though the market remains competitive and innovation-driven, so the company must keep investing to defend this edge.

Innovation and R&D

Innovation and R&D Innovation is clearly a core pillar. Agilent leads in chromatography and mass spectrometry systems and has strong offerings in genomics, such as its targeted sequencing solutions. It combines advanced instruments with intelligent software and informatics to support more automated, data-rich labs. The company is also pushing into high-growth areas like biopharmaceuticals, RNA-based therapeutics, companion diagnostics, and cell and gene therapy tools, supported by sizeable capacity investments and targeted acquisitions. Increasing use of artificial intelligence and analytics in its platforms suggests an eye on the “smart lab” of the future. The main execution risk is turning these promising innovation bets and capacity expansions into sustained, profitable growth amid fast-changing science and technology landscapes.

Summary

Overall, Agilent looks like a mature, high-quality life sciences tools and diagnostics company with strong profitability, good cash generation, and a defendable competitive position. The main financial watchpoints are slower recent revenue growth and a gradual increase in debt. On the opportunity side, the company is well placed to benefit from long-term trends in biopharma, precision medicine, and advanced lab automation, supported by active innovation and services that embed it deeply with customers. Future performance will depend on reigniting growth while maintaining its strong margins and managing leverage prudently in a competitive, innovation-heavy industry.

NEWS

November 24, 2025 · 4:10 PM UTC

Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

Read more

November 19, 2025 · 4:15 PM UTC

Agilent Announces Cash Dividend of 25.5 Cents Per Share

Read more

November 18, 2025 · 5:10 PM UTC

Agilent to Participate in Citi's 2025 Global Healthcare Conference

Read more

November 12, 2025 · 8:00 AM UTC

Agilent Research Catalyst (ARC) Award Presented to UC Davis for Breakthroughs in Peptide Therapeutics

Read more

October 30, 2025 · 4:15 PM UTC

Agilent to Announce Fourth-Quarter Fiscal Year 2025 Financial Results on Nov. 24

Read more